Viral Vector– tag –
-
Mayo Clinic Leads ARPA-H Initiative to Advance Gene-Editing Therapies for Rare Immune Diseases, Integrating CRISPR and Novel Delivery for Over 500 Inborn Errors of Immunity
Mayo Clinic News Network USA Overview Mayo Clinic is participating in a 5-year collaborative research initiative, funded by an ARPA-H grant, to accelerate the development of gene-editing therapies for rare immune diseases. This initiativ... -
CRISPR Frontiers 2026: Innovations in DSB-Independent Editing and Delivery Systems Boost Genome Editing Precision and Stability
Addgene Blog USA Overview The 'Genome Engineering: CRISPR Frontiers 2026' conference reported significant evolution in CRISPR technology towards precise, double-strand break (DSB)-independent editing. Researchers are focusing on enhancin... -
Next-Generation CRISPR Tools Revolutionize Precise Gene Editing, Bypassing Double-Strand Breaks for Enhanced Therapeutic Safety and Consistency
News-Medical.net USA Overview Next-generation CRISPR technologies are fundamentally transforming cell and gene therapy by enabling precise gene editing without relying on double-strand DNA breaks (DSBs). Advances in base editing, prime e... -
FDA Approves Novo Nordisk’s Pasatru for FOP, Accelerates Approval for Tudriqev Combination in Melanoma, and Greenlights mFLUSIVA mRNA Flu Vaccine
Drugs.com USA Overview In August 2026, the FDA approved several key new drugs. Novo Nordisk's Pasatru (garetosmab-grts) gained approval for adults with Fibrodysplasia Ossificans Progressiva (FOP). An accelerated approval was granted for ... -
2026 ‘In Vivo CRISPR Medicine’ Symposium to Focus on Commercialization and Scalable Deployment of In Vivo Genome Editing
CRISPR Medicine News (CMN x CSGCT Virtual Symposium) USA Overview The upcoming 'In Vivo CRISPR Medicine: From Scientific Promise to Patients at Scale' virtual symposium on September 3, 2026, will highlight the transition of in vivo genom... -
Virica Biotech Announces CAR-T Lentivirus Manufacturing Innovations and AAV Production Optimization with FUJIFILM
Virica Biotech Canada Overview Virica Biotech has announced innovative advancements in lentiviral vector manufacturing for CAR-T therapies, highlighted by a May 19, 2026, poster presentation featuring high productivity and smarter purifi... -
PackGene Biotech’s π-alpha 293 Platform Achieves 10x AAV Production Amplification, Up to 1e+17vg/Batch, Supporting Remedium Bio’s Gene Therapy Advancement
PackGene Biotech China Overview PackGene Biotech announced its innovative π-alpha 293 AAV high-yield platform, capable of amplifying adeno-associated virus (AAV) production up to 10-fold and achieving an impressive yield of up to 1e+17vg... -
Viral Vector Manufacturing: Global Leaders Scale Up Capacity with Advanced Platforms and Strategic Acquisitions
The Business Research Company International Overview The viral vector manufacturing market is experiencing rapid expansion as major players intensify efforts to scale production for gene therapies and vaccines. Recent strategic moves inc... -
Yeasen and Porton Advanced Form Strategic Alliance to Fortify CGT Supply Chain and Drive Innovation
Company Announcement China Overview Yeasen Biotechnology and Porton Advanced Solutions have established a strategic partnership aimed at fortifying the cell and gene therapy (CGT) supply chain and fostering innovation. The alliance will ... -
In Vivo CAR-T Cell Therapy Demonstrates Clinical Proof-of-Concept with AI Acceleration: Enabling Direct In-Body Immune Cell Gene Editing Towards ‘Off-the-Shelf Biologics’
OncoDaily International Overview While autologous CAR-T cell therapy yields durable remissions in B-cell malignancies, its delivery model faces persistent challenges. In vivo CAR-T emerges as a radically different approach, delivering CA...
